WIXOM, Mich., May 26, 2020 -- Rockwell Medical, Inc. (Nasdaq: RMTI) (“Rockwell Medical” or the “Company”), a biopharmaceutical company dedicated to transforming anemia.
WIXOM, Mich., April 20, 2020 -- Rockwell Medical, Inc. (Nasdaq: RMTI) (“Rockwell Medical” or the “Company”), a biopharmaceutical company dedicated to transforming anemia.
Medical Resource Acquisition Group, LLC (MRAG) an investment company focused on facilitating the advancement of innovative healthcare companies, announces that it has been receiving overwhelming support from Rockwell shareholders who are in favor of Rockwell Medical (RMTI; NASDAQ) receiving $15 million in funding and having three new Directors with successful experience and worldwide global, financial, and strategic contacts replace Directors Lisa Colleran, John Cooper and Mark Ravich. In light of the tremendous support for MRAG a weblink has been set up on the MRAG website. MRAG is backed by Canadian, UAE based businessman Khurram Shroff, who is an award- winning, global banking and finance leader, featured in the prestigious list of the “Top 100 Most Powerful and Influential Muslims in Great Britain and the World” by Power100.
We at Insider Monkey have gone over 821 13F filings that hedge funds and prominent investors are required to file by the SEC The 13F filings show the funds' and investors' portfolio positions as of March 31st, near the height of the coronavirus market crash. In this article, we look at what those funds think […]
NEW YORK, NY / ACCESSWIRE / March 12, 2020 / Rockwell Medical, Inc. (NASDAQ:RMTI) will be discussing their earnings results in their 2019 Fourth Quarter Earnings call to be held on March 12, 2020 at 4:30 ...
MRAG, an investment company focused on facilitating the advancement of innovative healthcare companies, which offered Rockwell Medical (RMTI; NASDAQ) funding of $15 million and put up a slate of three new directors to replace current Directors Lisa Colleran, John Cooper and Mark Ravich, announces that it properly delivered notice of MRAG’s three director nominations under Rockwell’s Bylaws and prescribed advance notice period, entirely refuting Rockwell’s assertion otherwise. MRAG maintains and, as confirmed by its legal counsel Loeb & Loeb, that it, without question, correctly submitted its slate of directors for the upcoming annual shareholder meeting and that this was done in accordance with the bylaws of Rockwell Medical and the state laws of Delaware.
Benzinga is covering every angle of how the coronavirus affects the financial world. For daily updates, sign up for our coronavirus newsletter.Biotech stocks went on a roller coaster ride in the week ended March 20 amid the market-wide COVID-19 sell-off. Activity remained light amid the cancellation of many medical meetings.The COVID-19 treatment and vaccine development news flow was front and center, as biopharma and diagnostics companies scrambled to capitalize on the need presented by the pandemic.This news flow is likely to continue into the unfolding week, with companies already in the fray providing updates and new entrants making announcements.View more earnings on IBBRelated Link: 8 Biotechs With Coronavirus Vaccines In DevelopmentThe following are other catalysts that could move stocks in the biotech space: PDUFA Dates The FDA is scheduled to announced its verdict on Bristol-Myers Squibb Co's (NYSE: BMY) NDA for ozanimod as a treatment option for patients with relapsing forms of multiple sclerosis. (Wednesday)IntelGenx Technologies Corp. OTCMKTS: (IGXT)'s NDA for rizaport versafilm for the treatment of acute migraine is pending before the FDA, with the target action day fixed for Thursday. The company has faced three rejections for the investigational drug in the past.The FDA is also expected to rule on Rockwell Medical Inc's (NASDAQ: RMTI) sNDA for intravenous formulation of anemia drug Triferic. (Saturday)Earnings Monday * DiaMedica Therapeutics Inc (NASDAQ: DMAC) (after the close) * Tuesday * Thermogenesis Holdings Inc (NASDAQ: THMO) (after the close) * OpGen Inc (NASDAQ: OPGN) (after the close) * Onconova Therapeutics Inc (NASDAQ: ONTX) (after the close)Wednesday * Viela Bio Inc (NASDAQ: VIE) (after the close) * Biocept Inc (NASDAQ: BIOC) (after the close) * OncoCyte Corp (NYSE: OCX) (after the close) * HTG Molecular Diagnostics Inc (NASDAQ: HTGM) (after the close) * Eyenovia Inc (NASDAQ: EYEN) (after the close) * Exagen Inc (NASDAQ: XGN) (after the close)Thursday * Celsion Corporation (NASDAQ: CLSN (before the market open) * Entera Bio Ltd (NASDAQ: ENTX) (before the market open) * TFF Pharmaceuticals Inc (NASDAQ: TFFP) (before the market open) * IGM Biosciences Inc (NASDAQ: IGMS) (after the close) * NovaBay Pharmaceuticals, Inc. (NYSE: NBY) (after the close) * Vermillion, Inc. (NASDAQ: VRML) (after the close)Friday * TELA Bio Inc (NASDAQ: TELA) (before the market open) * Zyla Life Sciences (OTC: ZCOR) (before the market open)IPO Quiet Period Expiry Passage Bio Inc (NASDAQ: PASG)See more from Benzinga * The Daily Biotech Pulse: Mylan Ramps Up Manufacturing Of Potential COVID-19 Drug, Lexicon Stops Study Early, Masimo To Buy German Ventilation Company * The Daily Biotech Pulse: Pfizer's Eczema Drug Aces Latestage Study, Orphan Drug Designation For Dicerna, Dyadic's COVID-19 Connection(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Rockwell Medical (RMTI) delivered earnings and revenue surprises of 8.33% and -6.47%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
Rockwell Medical (RMTI) delivered earnings and revenue surprises of 0.00% and 0.96%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
With this approval, Triferic AVNU joins Triferic Dialysate as the only FDA-approved products indicated to replace iron and maintain hemoglobin in adult patients with hemodialysis-dependent chronic kidney disease. Triferic is a novel, physiologic iron maintenance therapy that provides bioavailable iron to replace iron lost during every dialysis treatment and maintain hemoglobin.
Medical Resource Acquisition Group, LLC (MRAG), an investment company focused on facilitating the advancement of innovative healthcare companies, announces that it remains focused on replacing Rockwell Medical, Inc. (RMTI; NASDAQ) Directors Lisa Colleran, John Cooper and Mark Ravich. MRAG believes Director’s Colleran, Cooper and Ravich have been largely responsible for the destruction in value of the RMTI share price, which under their guidance, or lack thereof, has lost approximately 84% of its value and plunged to an all-time low trading recently at $1.12 per share. MRAG views the Rockwell Board’s decision to announce in a press release to shareholders that it consummated a debt financing up to $35 million, and that it was a non-dilutive financing done at the urging of shareholders, to be misleading, deceptive and not in the best interest of the shareholders of Rockwell.
WIXOM, Mich., March 31, 2020 -- Rockwell Medical, Inc. (NASDAQ:RMTI) (“Rockwell Medical” or the "Company"), a biopharmaceutical company dedicated to transforming anemia.
Medical Resource Acquisition Group, LLC (MRAG), an investment company focused on facilitating the advancement of innovative healthcare companies, intends to ensure Rockwell Medical, Inc. (RMTI; NASDAQ) shareholders will not have their voting rights suppressed by the Rockwell Board of Directors, and intends to use all means available, including litigation, to protect the Rockwell shareholder’s right to vote for new, independent directors and improved, transparent Board governance. On March 4, 2020, prior to a phone conference with Rockwell’s Chairman of the Board, John McLaughlin, MRAG submitted the necessary documents for their three new directors to be nominated for election at Rockwell’s next annual meeting, and after receiving confirmation from Rockwell prior to the March 8, 2020 deadline of receipt of the nomination materials, the Company waited until after the nomination deadline to note its technical objections to MRAG’s nominations and has since publicly stated that they intend not to recognize the MRAG submission.
WIXOM, Mich., March 10, 2020 -- Rockwell Medical, Inc. (NASDAQ:RMTI) (“Rockwell Medical” or the “Company”), a biopharmaceutical company dedicated to transforming anemia.
Rockwell Medical (RMTI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
While MRAG has continued its attempts to confuse shareholders into believing otherwise, the Company has been abundantly clear in its communications with MRAG and its advisors that MRAG’s three director nominees will not stand for election at the Company’s 2020 annual meeting of stockholders. The Company will also make copies of such correspondence available on our website, https://ir.rockwellmed.com/.
-Q1 2020 revenue of $15.9 million- -Received FDA Approval of Triferic® AVNUTM- -Significant expansion of Triferic (ferric pyrophosphate citrate) Dialysate Evaluation Programs.
WIXOM, Mich., March 11, 2020 -- Rockwell Medical, Inc. (NASDAQ:RMTI) (“Rockwell Medical” or the “Company”), a biopharmaceutical company dedicated to transforming anemia.
– Company reports positive adoption trends for Dialysate Triferic® (ferric pyrophosphate citrate), highlighted by 77% increase in clinics under contract – -- Signed contract.
"We are pleased to partner with Innovatus on this transaction," said Stuart Paul, President and Chief Executive Officer of Rockwell Medical. "This financing will provide flexibility as we continue our mission to advance our novel therapeutic, Triferic, and to transform the way anemia is managed around the world," concluded Mr. Paul.